STB-C017 is an IDO/TDO dual inhibitor, derived from Syntekabio’s proprietary drug discovery artificial intelligence solution, demonstrated powerful immuno-oncologic effect.

Triple combination therapy of STB-C017, PD-1, CTLA-4 immune checkpoint inhibitors (ICIs) presented complete remission (CR) of tumor and long-term survival benefit.

Subsequent nonclinical development and collaborative efforts might yield IND submission within 2 years

DAEJEON, South Korea, May 15, 2020 /PRNewswire/ — Syntekabio (KOSDAQ: 226330), an AI and NGS based drug development company, presented the result of STB-C017 animal experiments, a small molecule IDO/TDO dual inhibitor derived by Syntekabio’s AI drug discovery solution, at the 2020 American Association for Cancer Research (AACR) Annual Meeting, today at 00:00 EDT.

The triple combination of STB-C017, aPD-1 and aCTLA-4 prolongs overall survival

Chan Kim, M.D., Ph.D., associate professor of CHA Bundang Medical Center and the